Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer

A. L. Feldman, L. Tamarkin, G. F. Paciotti, B. W. Simpson, W. M. Linehan, J. C. Yang, W. E. Fogler, E. M. Turner, Jr Alexander H.R., S. K. Libutti

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Clear cell renal carcinoma (CCRC) is a highly angiogenic tumor known to secrete vascular endothelial cell growth factor (VEGF). Endostatin is an endogenous antiangiogenic agent with antitumor activity in mice. The purpose of this study was to evaluate serum levels of endostatin in normal subjects and in patients with CCRC and to examine the relationship of these levels to circulating VEGF levels. Fifteen patients (mean age, 48 years) on a clinical protocol for stage IV CCRC at the National Cancer Institute were included in the study. Archived prenephrectomy serum samples were analyzed for endostatin and VEGF concentrations. Endostatin and VEGF levels were compared with those of an age-matched group of volunteer blood donors (n = 18) using a competitive enzyme immunoassay. Data were analyzed using the Mann-Whitney U test and the Spearman rank correlation. Median serum endostatin levels were 24.6 ng/ml (range, 15.1-54.0 ng/ml) in CCRC patients versus 14.1 ng/ml (range, 1.0-19.3 ng/ml) in healthy controls (P < 0.0001). Median VEGF levels were 3.4 ng/ml (range, 0.1-11.2 ng/ml) and 2.5 ng/ml (range, 0.1-4.2 ng/ml), respectively (P = 0.065). A highly significant correlation was observed between endostatin and VEGF levels among the CCRC patients (r = 0.81, P = 0.0003) but not among controls (r = -0.22, P = 0.37). Endostatin levels are detectable in serum from healthy subjects as well as from CCRC patients. Levels are significantly elevated and correlate with VEGF levels in CCRC patients. Elucidating the nature of this correlation may lend insight into the regulation of tumor angiogenesis in patients with renal cancer.

Original languageEnglish (US)
Pages (from-to)4628-4634
Number of pages7
JournalClinical Cancer Research
Volume6
Issue number12
StatePublished - 2000
Externally publishedYes

Fingerprint

Endostatins
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Serum
Angiogenesis Inhibitors
National Cancer Institute (U.S.)
Kidney Neoplasms
Clinical Protocols
Nonparametric Statistics
Blood Donors
Immunoenzyme Techniques
Volunteers
Neoplasms
Healthy Volunteers
Research Design
Age Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Feldman, A. L., Tamarkin, L., Paciotti, G. F., Simpson, B. W., Linehan, W. M., Yang, J. C., ... Libutti, S. K. (2000). Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clinical Cancer Research, 6(12), 4628-4634.

Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. / Feldman, A. L.; Tamarkin, L.; Paciotti, G. F.; Simpson, B. W.; Linehan, W. M.; Yang, J. C.; Fogler, W. E.; Turner, E. M.; Alexander H.R., Jr; Libutti, S. K.

In: Clinical Cancer Research, Vol. 6, No. 12, 2000, p. 4628-4634.

Research output: Contribution to journalArticle

Feldman, AL, Tamarkin, L, Paciotti, GF, Simpson, BW, Linehan, WM, Yang, JC, Fogler, WE, Turner, EM, Alexander H.R., J & Libutti, SK 2000, 'Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer', Clinical Cancer Research, vol. 6, no. 12, pp. 4628-4634.
Feldman, A. L. ; Tamarkin, L. ; Paciotti, G. F. ; Simpson, B. W. ; Linehan, W. M. ; Yang, J. C. ; Fogler, W. E. ; Turner, E. M. ; Alexander H.R., Jr ; Libutti, S. K. / Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 12. pp. 4628-4634.
@article{d91c864c50724c5c9d3ac1c8bf3cee3f,
title = "Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer",
abstract = "Clear cell renal carcinoma (CCRC) is a highly angiogenic tumor known to secrete vascular endothelial cell growth factor (VEGF). Endostatin is an endogenous antiangiogenic agent with antitumor activity in mice. The purpose of this study was to evaluate serum levels of endostatin in normal subjects and in patients with CCRC and to examine the relationship of these levels to circulating VEGF levels. Fifteen patients (mean age, 48 years) on a clinical protocol for stage IV CCRC at the National Cancer Institute were included in the study. Archived prenephrectomy serum samples were analyzed for endostatin and VEGF concentrations. Endostatin and VEGF levels were compared with those of an age-matched group of volunteer blood donors (n = 18) using a competitive enzyme immunoassay. Data were analyzed using the Mann-Whitney U test and the Spearman rank correlation. Median serum endostatin levels were 24.6 ng/ml (range, 15.1-54.0 ng/ml) in CCRC patients versus 14.1 ng/ml (range, 1.0-19.3 ng/ml) in healthy controls (P < 0.0001). Median VEGF levels were 3.4 ng/ml (range, 0.1-11.2 ng/ml) and 2.5 ng/ml (range, 0.1-4.2 ng/ml), respectively (P = 0.065). A highly significant correlation was observed between endostatin and VEGF levels among the CCRC patients (r = 0.81, P = 0.0003) but not among controls (r = -0.22, P = 0.37). Endostatin levels are detectable in serum from healthy subjects as well as from CCRC patients. Levels are significantly elevated and correlate with VEGF levels in CCRC patients. Elucidating the nature of this correlation may lend insight into the regulation of tumor angiogenesis in patients with renal cancer.",
author = "Feldman, {A. L.} and L. Tamarkin and Paciotti, {G. F.} and Simpson, {B. W.} and Linehan, {W. M.} and Yang, {J. C.} and Fogler, {W. E.} and Turner, {E. M.} and {Alexander H.R.}, Jr and Libutti, {S. K.}",
year = "2000",
language = "English (US)",
volume = "6",
pages = "4628--4634",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer

AU - Feldman, A. L.

AU - Tamarkin, L.

AU - Paciotti, G. F.

AU - Simpson, B. W.

AU - Linehan, W. M.

AU - Yang, J. C.

AU - Fogler, W. E.

AU - Turner, E. M.

AU - Alexander H.R., Jr

AU - Libutti, S. K.

PY - 2000

Y1 - 2000

N2 - Clear cell renal carcinoma (CCRC) is a highly angiogenic tumor known to secrete vascular endothelial cell growth factor (VEGF). Endostatin is an endogenous antiangiogenic agent with antitumor activity in mice. The purpose of this study was to evaluate serum levels of endostatin in normal subjects and in patients with CCRC and to examine the relationship of these levels to circulating VEGF levels. Fifteen patients (mean age, 48 years) on a clinical protocol for stage IV CCRC at the National Cancer Institute were included in the study. Archived prenephrectomy serum samples were analyzed for endostatin and VEGF concentrations. Endostatin and VEGF levels were compared with those of an age-matched group of volunteer blood donors (n = 18) using a competitive enzyme immunoassay. Data were analyzed using the Mann-Whitney U test and the Spearman rank correlation. Median serum endostatin levels were 24.6 ng/ml (range, 15.1-54.0 ng/ml) in CCRC patients versus 14.1 ng/ml (range, 1.0-19.3 ng/ml) in healthy controls (P < 0.0001). Median VEGF levels were 3.4 ng/ml (range, 0.1-11.2 ng/ml) and 2.5 ng/ml (range, 0.1-4.2 ng/ml), respectively (P = 0.065). A highly significant correlation was observed between endostatin and VEGF levels among the CCRC patients (r = 0.81, P = 0.0003) but not among controls (r = -0.22, P = 0.37). Endostatin levels are detectable in serum from healthy subjects as well as from CCRC patients. Levels are significantly elevated and correlate with VEGF levels in CCRC patients. Elucidating the nature of this correlation may lend insight into the regulation of tumor angiogenesis in patients with renal cancer.

AB - Clear cell renal carcinoma (CCRC) is a highly angiogenic tumor known to secrete vascular endothelial cell growth factor (VEGF). Endostatin is an endogenous antiangiogenic agent with antitumor activity in mice. The purpose of this study was to evaluate serum levels of endostatin in normal subjects and in patients with CCRC and to examine the relationship of these levels to circulating VEGF levels. Fifteen patients (mean age, 48 years) on a clinical protocol for stage IV CCRC at the National Cancer Institute were included in the study. Archived prenephrectomy serum samples were analyzed for endostatin and VEGF concentrations. Endostatin and VEGF levels were compared with those of an age-matched group of volunteer blood donors (n = 18) using a competitive enzyme immunoassay. Data were analyzed using the Mann-Whitney U test and the Spearman rank correlation. Median serum endostatin levels were 24.6 ng/ml (range, 15.1-54.0 ng/ml) in CCRC patients versus 14.1 ng/ml (range, 1.0-19.3 ng/ml) in healthy controls (P < 0.0001). Median VEGF levels were 3.4 ng/ml (range, 0.1-11.2 ng/ml) and 2.5 ng/ml (range, 0.1-4.2 ng/ml), respectively (P = 0.065). A highly significant correlation was observed between endostatin and VEGF levels among the CCRC patients (r = 0.81, P = 0.0003) but not among controls (r = -0.22, P = 0.37). Endostatin levels are detectable in serum from healthy subjects as well as from CCRC patients. Levels are significantly elevated and correlate with VEGF levels in CCRC patients. Elucidating the nature of this correlation may lend insight into the regulation of tumor angiogenesis in patients with renal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034488630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034488630&partnerID=8YFLogxK

M3 - Article

C2 - 11156212

AN - SCOPUS:0034488630

VL - 6

SP - 4628

EP - 4634

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -